Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHOA | P61586 | 8/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17729030 | 0.87 | RHOA (0.68) | RHOAPOLBALDH1A1MEN1NPC1 | |
| SCHEMBL17729019 | 0.83 | RHOA (0.73) | RHOAPOLBKMT2A | |
| SCHEMBL17729095 | 0.82 | RHOA (0.83) | RHOAPOLBRAB9AKMT2A | |
| SCHEMBL29658266 | 0.82 | RHOA (1.00) | RHOAPOLBALDH1A1HPGDRAB9A | |
| SCHEMBL17728988 | 0.82 | RHOA (1.00) | RHOAPOLBALDH1A1HPGDRAB9A | |
| SCHEMBL17729080 | 0.82 | RHOA (0.77) | RHOAPOLBALDH1A1 | |
| SCHEMBL17729013 | 0.82 | RHOA (0.83) | RHOAPOLBRAB9AKMT2A | |
| SCHEMBL17773275 | 0.82 | RHOA (0.61) | RHOAPOLBALDH1A1MEN1RAB9A | |
| SCHEMBL17773186 | 0.81 | RHOA (0.72) | RHOAPOLBALDH1A1 | |
| SCHEMBL17729072 | 0.81 | RHOA (0.70) | RHOAPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3215150-B1 | INHIBITORS OF MYOCARDIN-RELATED TRANSCRIPTION FACTOR AND SERUM RESPONSE FACTOR (MRTF/SRF)-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME | UNIV MICHIGAN REGENTS (US) | 2022-07-20 | — | — | EP | disclosed |
| US-10662183-B2 | Inhibitors of myocardin-related transcription factor and serum response factor (MRTF/SRF)-mediated gene transcription and methods for use of the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-05-26 | — | — | US | disclosed |
| US-10662183-B2 | Inhibitors of myocardin-related transcription factor and serum response factor (MRTF/SRF)-mediated gene transcription and methods for use of the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-05-26 | — | — | US | disclosed |
| EP-3215150-A2 | INHIBITORS OF MYOCARDIN-RELATED TRANSCRIPTION FACTOR AND SERUM RESPONSE FACTOR (MRTF/SRF)-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME | The Regents of The University of Michigan (US) | 2017-09-13 | — | — | EP | disclosed |
| US-20160145251-A1 | INHIBITORS OF MYOCARDIN-RELATED TRANSCRIPTION FACTOR AND SERUM RESPONSE FACTOR (MRTF/SRF)-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2016-05-26 | — | — | US | disclosed |
| US-20160145251-A1 | INHIBITORS OF MYOCARDIN-RELATED TRANSCRIPTION FACTOR AND SERUM RESPONSE FACTOR (MRTF/SRF)-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2016-05-26 | — | — | US | disclosed |
| US-20160145251-A1 | INHIBITORS OF MYOCARDIN-RELATED TRANSCRIPTION FACTOR AND SERUM RESPONSE FACTOR (MRTF/SRF)-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2016-05-26 | — | — | US | disclosed |
| WO-2016073847-A2 | INHIBITORS OF MYOCARDIN-RELATED TRANSCRIPTION FACTOR AND SERUM RESPONSE FACTOR (MRTF/SRF)-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-05-12 | — | — | WO | disclosed |
| WO-2016073847-A2 | INHIBITORS OF MYOCARDIN-RELATED TRANSCRIPTION FACTOR AND SERUM RESPONSE FACTOR (MRTF/SRF)-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145251-A1 | INHIBITORS OF MYOCARDIN-RELATED TRANSCRIPTION FACTOR AND SERUM RESPONSE FACTOR (MRTF/SRF)-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME | SREBF1, SREBF2, BPTF | RHOA 229/4885POLB 3134/4885KEAP1 865/4885 |
| US-10662183-B2 | Inhibitors of myocardin-related transcription factor and serum response factor (MRTF/SRF)-mediated gene transcription and methods for use of the same | SREBF1, SREBF2, BPTF | RHOA 229/4885POLB 3134/4885KEAP1 865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.